CVS Health Corp vs Sony Group Corp — how do they compare? CVS Health Corp trades at $86.43 (market cap $112.49B), while Sony Group Corp trades at $24.19 (market cap $138.06B). The key difference: Sony Group Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Sony Group Corp for 96 Days on average.
| CVS | SONY | |
|---|---|---|
Market Cap | $112.49B | $138.06B |
Volume | 8,467,392 | 3,986,731 |
Sector | Health | Technology |
52-Week High | $110.60 | $30.26 |
52-Week Low | $70.08 | $19.32 |
Typical Hold Time | 83 Days | 96 Days |
Enterprise Value | $174.83B | $135.96B |
Dividend Yield | 3.02% | 0.67% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Sony trades at $23.95, up 0.42% with neutral technical signals. The company shows strong cash flow generation ($2.32T operating cash flow in 2025) and beat earnings expectations in two of the last three quarters. However, 2026 projections indicate potential challenges with negative net income margin and declining revenue. Analyst sentiment remains positive with 11 buy ratings and no sell recommendations among 16 analysts covering the stock.
Sony presents a mixed investment case with solid entertainment assets and cash flow strength offset by near-term profitability concerns. The stock's reasonable valuation (P/E 19.93, P/S 1.75) and strong analyst support provide upside potential, but investors must monitor execution against 2026 guidance and competitive pressures in entertainment markets.
Trailing returns across standard periods
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →